ACC: Novel Anticoagulant May Sidestep Bleeding Risk - CME Teaching Brief® - MedPage Today: "NEW ORLEANS, March 25 -- An investigational oral thrombin receptor antagonist led to a trend toward reduced fatal and non-fatal cardiac events, with a low bleeding risk, in a phase II trial of patients with percutaneous coronary interventions, mostly stenting.
In the early results on the safety of SCH 530348, the first oral thrombin receptor antagonist, there was a slight but not statistically significant increase in major and minor bleeding events -- 4% versus 3.3% for placebo -- with a 40-mg dose. In further trials, 40 mg is the investigational dose that is expected to be pursued."
No comments:
Post a Comment